Scientific and Regulatory Policy Committee: Recommended ("Best") Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies.
about
Characterizing "Adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop.Principles for Assessing Adversity in Toxicologic Clinical Pathology.Is It Adverse, Nonadverse, Adaptive, or Artifact?Role of Anatomic Pathology in Skeletal Evaluations: Applying INHAND Diagnostic Criteria.Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular.
P2860
Scientific and Regulatory Policy Committee: Recommended ("Best") Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies.
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Scientific and Regulatory Poli ...... Data from Nonclinical Studies.
@ast
Scientific and Regulatory Poli ...... Data from Nonclinical Studies.
@en
type
label
Scientific and Regulatory Poli ...... Data from Nonclinical Studies.
@ast
Scientific and Regulatory Poli ...... Data from Nonclinical Studies.
@en
prefLabel
Scientific and Regulatory Poli ...... Data from Nonclinical Studies.
@ast
Scientific and Regulatory Poli ...... Data from Nonclinical Studies.
@en
P2093
P2860
P356
P1476
Scientific and Regulatory Poli ...... Data from Nonclinical Studies.
@en
P2093
Brad Bolon
James Popp
John Burkhardt
Peter Greaves
Roy Kerlin
Sabine Francke
Vince Meador
P2860
P304
P356
10.1177/0192623315623265
P407
P577
2015-12-23T00:00:00Z